Die ACIP het die taak gehad om twee vrae te bespreek:
Does ACIP have enough information to make interim age or risk factor-based recommendations for use of the Janssen vaccine?
What recommendation does ACIP feel is appropriate today given current available information for use of the Janssen vaccine?
Many committee members felt there was insufficient data to make an evidence-based decision on Wednesday. Several unknowns include the true background incidence of CVST with low platelet count, specific risk factors, ability to compare thrombotic cases post-vaccination between AstraZeneca and J&J vaccines, and true incidence of cases specific to J&J vaccine recipients.
Officials emphasized the extended pause did not indicate increased concern but instead an attempt to better characterize the risk.
The cases under review involved six females between ages 18 en 48, whose serious adverse events occurred within six to 13 days of vaccination.
The instances have been described as “extremely rare” by the FDA, and the agencies recommended the pause Tuesday “out of an abundance of caution” partly due to how the blood clots must be treated.
The committee said that by Friday it would determine when to next meet and discuss the data.
Dit is 'n ontwikkelende verhaal, please continue to check back for updates.
Fox News’ Alexandria Hein contributed to this report.